Page last updated: 2024-09-04

moxifloxacin and Respiratory Tract Infections

moxifloxacin has been researched along with Respiratory Tract Infections in 61 studies

Research

Studies (61)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (1.64)	18.2507
2000's	40 (65.57)	29.6817
2010's	19 (31.15)	24.3611
2020's	1 (1.64)	2.80

Authors

Authors	Studies
Chang, CL; Jeong, J; Jeong, SH; Jung, HJ; Kim, HR; Kim, S; Lee, EY; Lee, JN; Shin, JH	1
Li, W; Liu, Y; Wang, M; Xu, X; Ye, X; Zhang, H; Zhu, D	1
Inagaki, H; Kitamura, T; Komoriya, S; Kuroyanagi, J; Miyauchi, RN; Nagamochi, M; Odagiri, T; Sugimoto, Y; Takahashi, H	1
Bax, B; Brooks, G; Brown, BS; Brown, P; Cailleau, N; Chen, D; Dabbs, S; Davies, DT; Esken, JM; Giordano, I; Gwynn, MN; Hennessy, AJ; Hoover, JL; Jones, GE; Kusalakumari Sukmar, SK; Markwell, RE; Miles, TJ; Minthorn, EA; Pearson, ND; Rittenhouse, S	1
Inagaki, H; Kitamura, T; Komoriya, S; Nagamochi, M; Odagiri, T; Takahashi, H	1
Bhagwat, S; Bhawsar, S; Deshpande, P; Joshi, S; Patel, M; Yeole, R	1
Li, HQ; Ning, W; Wang, JX; Zhang, F	1
Fanlo, P; Heras-Mulero, H; Plaza-Ramos, P; Zubicoa, A	1
Borrego, J; Cobo, F; Navarro-Marí, JM; Rodríguez-Granger, J; Sampedro, A	1
Andersen, ÅB; Gynthersen, R; Katzenstein, TL; Qvist, T	1
Chatzika, K; Kioumis, I; Kontou, P; Manika, K; Papaioannou, M; Pitsiou, G; Sionidou, M	1
Noreddin, AM; Salem, AH	1
Ji, S; Wang, N; Yang, W; Zhang, Y; Zhao, X; Zhu, L	1
Carral, N; Lukas, JC; Oteo, I; Suarez, E	1
Mattappallil, A; Mergenhagen, KA; Ott, MC; Ruh, CA; Schroeck, JL; Sellick, JA	1
Endo, J; Funaguchi, N; Ito, F; Kaito, D; Kamamiya, F; Koumei, Y; Minatoguchi, S; Mori, H; Mori, M; Morishita, M; Ohno, Y; Toyoshi, S	1
Chen, L; Chen, X; Jia, X; Li, N; Liu, W; Sun, H; Tong, H; Xiang, R; Xu, Y; Zhang, F; Zhang, J; Zhao, H	1
Kocsis, B; Szabo, D	1
Decramer, M; Simoens, S	1
Anzueto, A; Miravitlles, M	1
Dalhoff, A; Jacobs, E; Korfmann, G	1
Tulkens, PM; Van Bambeke, F	1
Burkhardt, O; Welte, T	1
Malithong, A; Phiboonbanakit, D; Santiwatanakul, S; Srisangchan, P; Srisurat, N; Susaengrat, W; Tantisiriwat, W; Thamlikitkul, V; Thunyaharn, S; Tiengrim, S	1
Bettis, DI; Morshedi, RG; Moshirfar, M; Vitale, AT	1
Chapuzet, C; Duncombe, A; Gueit, I; Gueudry, J; Massy, N; Muraine, M	1
Coker, TJ	1
Allouch, PY; Courvalin, P; Decousser, JW; Leclercq, R	1
Amábile, C; García Rodríguez, JA; López, H; Muñoz Bellido, JL; Pedreira, W; Sader, H	1
Citron, DM; Goldstein, EJ; Schooley, S; Stein, GE; Tyrrell, KL	1
Iakovlev, VP; Polushkina, NR	1
Huisamen, A; Liebowitz, LD; Slabbert, M	1
Arcuri, P; Brar, JS; Celesk, RA; Church, DA; Faich, GA; Haverstock, DC; Kowalsky, SF; Morganroth, J; Whitehouse, AB	1
Daschner, F; Schmidt-Eisenlohr, E; Wenzler, S	1
Al-Kuwari, J; Elshafie, SS	1
Caeiro, JP; Iannini, PB	1
Hoepelman, I	1
Miravitlles, M	1
Hermsen, ED; Hovde, LB; Konstantinides, GN; Rotschafer, JC	1
Begaud, B; Funck-Brentano, C; Veyssier, P; Voirot, P	1
Bai, C; Chen, W; Li, Z; Wu, C	1
DeRyke, CA; Doern, GV; Du, X; Nicolau, DP; Sun, HK	1
Landen, H; Liu, LY	1
Davydow, DS; Reti, IM	1
Barrett, MS; Biedenbach, DJ; Croco, MA; Jones, RN	1
Balfour, JA; Lamb, HM	1
Nightingale, CH	1
Almaraz, F; Baquero, F; Cantón, R; Loza, E; Morosini, M; Negri, MC	1
Critchley, I; Engler, HD; Heinze, P; Jones, ME; Sahm, DF; Staples, AM; Thornsberry, C	1
Talan, DA	1
Krasemann, C; Meyer, J; Tillotson, G	1
Blondeau, JM; Hansen, GT	1
Ambler, J; Cardeñosa, O; Lemme, L; Lopez, H; Scarano, S; Smayevsky, J; Stepanik, D; Sucari, A; Vilches, V	1
Rossi, C; Sternon, J	1
Iakovlev, SV; Iakovlev, VP; Polushkina, NR	1
Betlejewska, K; Hryniewicz, W	1
Ling, ML; Tan, PL	1
Amyes, SG; Dorai-John, T; Thomson, CJ	1

Reviews

17 review(s) available for moxifloxacin and Respiratory Tract Infections

Article	Year
A pharmacoeconomic review of the management of respiratory tract infections with moxifloxacin. Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:10 Topics: Anti-Infective Agents; Aza Compounds; Bronchitis, Chronic; Community-Acquired Infections; Costs and Cost Analysis; Fluoroquinolones; Humans; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Respiratory Tract Infections; Sinusitis	2008
Moxifloxacin: a respiratory fluoroquinolone. Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:10 Topics: Anti-Bacterial Agents; Aza Compounds; Bronchitis, Chronic; Clinical Trials as Topic; Community-Acquired Infections; Fluoroquinolones; Humans; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Respiratory Tract Infections; Sinusitis	2008
Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug safety, 2009, Volume: 32, Issue:5 Topics: Anti-Infective Agents; Aza Compounds; Fluoroquinolones; Humans; Moxifloxacin; Quinolines; Respiratory Tract Infections	2009
10 years' experience with the pneumococcal quinolone moxifloxacin. Expert review of anti-infective therapy, 2009, Volume: 7, Issue:6 Topics: Anti-Bacterial Agents; Aza Compounds; Cross Infection; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Moxifloxacin; Quinolines; Randomized Controlled Trials as Topic; Respiratory Tract Infections; Streptococcus pneumoniae; Time Factors; Treatment Outcome	2009
Bilateral acute iris transillumination following systemic moxifloxacin for respiratory illness: report of two cases and review of the literature. Ocular immunology and inflammation, 2012, Volume: 20, Issue:4 Topics: Adult; Aged; Anti-Infective Agents; Antihypertensive Agents; Aza Compounds; Female; Fluoroquinolones; Humans; Iris Diseases; Male; Moxifloxacin; Ocular Hypertension; Pigment Epithelium of Eye; Quinolines; Respiratory Tract Infections; Trabecular Meshwork; Transillumination; Treatment Outcome	2012
[Moxifloxacin: results of clinical use]. Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2002, Volume: 47, Issue:10 Topics: Anti-Infective Agents; Aza Compounds; Bronchitis, Chronic; Clinical Trials as Topic; Fluoroquinolones; Humans; Moxifloxacin; Pneumonia; Quinolines; Respiratory Tract Infections; Sinusitis; Skin Diseases, Bacterial; Treatment Outcome	2002
Moxifloxacin (Avelox): a novel fluoroquinolone with a broad spectrum of activity. Expert review of anti-infective therapy, 2003, Volume: 1, Issue:3 Topics: Animals; Aza Compounds; Clinical Trials as Topic; Drugs, Investigational; Fluoroquinolones; Humans; Moxifloxacin; Quinolines; Respiratory Tract Infections	2003
[New fluoroquinolones: levofloxacin, moxifloxacin and gatifloxacin]. Nederlands tijdschrift voor geneeskunde, 2004, Oct-23, Volume: 148, Issue:43 Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Pneumonia; Quinolines; Respiratory Tract Infections	2004
Moxifloxacin in respiratory tract infections. Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:2 Topics: Aza Compounds; Clinical Trials as Topic; Community-Acquired Infections; Drug Resistance, Microbial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Respiratory Tract Infections	2005
[Cardiac tolerance of moxifloxacin: Clinical experience from a large observational French study in usual medical practice (IMMEDIAT study)]. Medecine et maladies infectieuses, 2006, Volume: 36, Issue:10 Topics: Anti-Infective Agents; Aza Compounds; Drug Tolerance; Fluoroquinolones; Heart; Humans; Moxifloxacin; Myocarditis; Quinolines; Respiratory Tract Infections	2006
Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs, 2000, Volume: 59, Issue:1 Topics: Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Respiratory Tract Infections	2000
Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics. Pharmacotherapy, 2000, Volume: 20, Issue:3 Topics: Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Drug Resistance, Microbial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Respiratory Tract Infections	2000
Clinical perspectives on new antimicrobials: focus on fluoroquinolones. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2001, Mar-15, Volume: 32 Suppl 1 Topics: Animals; Anti-Infective Agents; Aza Compounds; Consumer Product Safety; Drug Resistance, Microbial; Fluoroquinolones; Humans; Moxifloxacin; Quinolines; Respiratory Tract Infections	2001
Evaluation of the clinical microbiology profile of moxifloxacin. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2001, Mar-15, Volume: 32 Suppl 1 Topics: Anti-Infective Agents; Aza Compounds; Drug Resistance, Microbial; Fluoroquinolones; Humans; Moxifloxacin; Quinolines; Respiratory Tract Infections; Treatment Outcome	2001
Moxifloxacin: a review of the microbiological, pharmacological, clinical and safety features. Expert opinion on pharmacotherapy, 2001, Volume: 2, Issue:2 Topics: Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Drug Resistance, Microbial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Randomized Controlled Trials as Topic; Respiratory Tract Infections; Treatment Outcome	2001
[Third and fourth generation fluoroquinolones]. Revue medicale de Bruxelles, 2001, Volume: 22, Issue:5 Topics: Administration, Oral; Anti-Infective Agents; Aza Compounds; Belgium; Biological Availability; Drug Monitoring; Drug Resistance; Fluoroquinolones; Gemifloxacin; Humans; Intestinal Absorption; Levofloxacin; Moxifloxacin; Naphthyridines; Ofloxacin; Patient Selection; Pneumococcal Infections; Quinolines; Respiratory Tract Infections; Streptococcus pneumoniae; Time Factors; Treatment Outcome	2001
[Moxifloxacin--a novel antimicrobial preparation for treatment of respiratory infections]. Terapevticheskii arkhiv, 2001, Volume: 73, Issue:11 Topics: Anti-Infective Agents; Aza Compounds; Clinical Trials as Topic; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Moxifloxacin; Quinolines; Respiratory Tract Infections	2001

Trials

3 trial(s) available for moxifloxacin and Respiratory Tract Infections

Article	Year
Systemic inflammation and the effects of short-term antibiotic treatment for PPM positive patients with stable COPD. International journal of chronic obstructive pulmonary disease, 2019, Volume: 14 Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Bacteria; Bacterial Infections; China; Disease Progression; Drug Administration Schedule; Female; Humans; Inflammation Mediators; Male; Middle Aged; Moxifloxacin; Pulmonary Disease, Chronic Obstructive; Respiratory Tract Infections; Risk Factors; Sputum; Time Factors; Treatment Outcome	2019
Population pharmacokinetics of intravenous moxifloxacin 400 mg once-daily dosage in infected patients. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2014, Volume: 20, Issue:10 Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Female; Fluoroquinolones; Gastrointestinal Diseases; Humans; Male; Middle Aged; Models, Theoretical; Moxifloxacin; Nonlinear Dynamics; Prospective Studies; Respiratory Tract Infections; Urinary Tract Infections; Young Adult	2014
Clinical experience with moxifloxacin in patients with respiratory tract infections. The Annals of pharmacotherapy, 2004, Volume: 38, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Child; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Quinolines; Respiratory Tract Infections	2004

Other Studies

41 other study(ies) available for moxifloxacin and Respiratory Tract Infections

Article	Year
Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:7 Topics: Anti-Bacterial Agents; Community-Acquired Infections; DNA, Bacterial; Drug Resistance, Bacterial; Erythromycin; Fluoroquinolones; Genes, Bacterial; Hospitals; Humans; Korea; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Molecular Epidemiology; Mutation; Ofloxacin; Pneumococcal Infections; Polymerase Chain Reaction; Prevalence; Reserpine; Respiratory Tract Infections; Retrospective Studies; Streptococcus pneumoniae	2007
Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:5 Topics: Adhesins, Bacterial; Anti-Bacterial Agents; Child; China; Drug Resistance, Bacterial; Genes, rRNA; Humans; Macrolides; Microbial Sensitivity Tests; Mutation; Mycoplasma pneumoniae; Pneumonia, Mycoplasma; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Respiratory Tract Infections; RNA, Ribosomal, 23S; Sequence Analysis, DNA	2009
Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens. Journal of medicinal chemistry, 2013, Mar-14, Volume: 56, Issue:5 Topics: Animals; Anti-Bacterial Agents; Drug Design; Fluoroquinolones; Haemophilus influenzae; Male; Mice; Microbial Sensitivity Tests; Quinolones; Rats; Respiratory Tract Infections; Spiro Compounds; Staphylococcus aureus; Streptococcus pneumoniae	2013
Novel tricyclics (e.g., GSK945237) as potent inhibitors of bacterial type IIA topoisomerases. Bioorganic & medicinal chemistry letters, 2016, 05-15, Volume: 26, Issue:10 Topics: Animals; Anti-Bacterial Agents; Chemistry Techniques, Synthetic; DNA Topoisomerases, Type II; Dogs; Drug Evaluation, Preclinical; ERG1 Potassium Channel; Gram-Negative Anaerobic Bacteria; Gram-Positive Bacteria; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; Pneumococcal Infections; Rats; Respiratory Tract Infections; Topoisomerase II Inhibitors	2016
Design, Synthesis, and Biological Evaluation of Novel 7-[(3 aS,7 aS)-3 a-Aminohexahydropyrano[3,4- c]pyrrol-2(3 H)-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens. Journal of medicinal chemistry, 2018, 08-23, Volume: 61, Issue:16 Topics: Animals; Anti-Bacterial Agents; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; ERG1 Potassium Channel; Escherichia coli; Female; Humans; Macaca fascicularis; Male; Methicillin-Resistant Staphylococcus aureus; Mice, Inbred CBA; Microbial Sensitivity Tests; Pneumococcal Infections; Quinolines; Respiratory Tract Infections; Streptococcus pneumoniae	2018
WCK 1152, WCK 1153: Discovery and structure activity relationship for the treatment of resistant pneumococcal and staphylococcal respiratory infections. Bioorganic & medicinal chemistry letters, 2022, 05-01, Volume: 63 Topics: Anti-Bacterial Agents; DNA Gyrase; DNA Topoisomerase IV; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Piperidines; Respiratory Tract Infections; Staphylococcal Infections; Staphylococcus; Streptococcus pneumoniae; Structure-Activity Relationship	2022
Bilateral acute iris transillumination syndrome. A case report. Archivos de la Sociedad Espanola de Oftalmologia, 2018, Volume: 93, Issue:9 Topics: Acute Disease; Anti-Bacterial Agents; Diagnostic Errors; Female; Glaucoma, Open-Angle; Humans; Iris; Middle Aged; Moxifloxacin; Mydriasis; Respiratory Tract Infections; Syndrome; Uveitis, Anterior	2018
A rare case of pleural infection due to Propionibacterium acnes (Cutibacterium acnes). Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2018, Volume: 31, Issue:2 Topics: Aged; Anti-Bacterial Agents; Fluoroquinolones; Gram-Positive Bacterial Infections; Humans; Male; Microbial Sensitivity Tests; Moxifloxacin; Pleural Diseases; Propionibacterium acnes; Pulmonary Disease, Chronic Obstructive; Respiratory Tract Infections	2018
Mycobacterium brisbanense lung infection facilitated by steroid induced adrenal insufficiency. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2019, Volume: 127, Issue:2 Topics: Adrenal Insufficiency; Adult; Amikacin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Humans; Male; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Respiratory Tract Infections; Sputum	2019
Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections. International journal of antimicrobial agents, 2013, Volume: 42, Issue:3 Topics: Aged; Anti-Bacterial Agents; Aza Compounds; Female; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Male; Metabolic Clearance Rate; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Respiratory Tract Infections	2013
Moxifloxacin in lower respiratory tract infections: in silico simulation of different bacterial resistance and drug exposure scenarios. Journal of chemotherapy (Florence, Italy), 2014, Volume: 26, Issue:2 Topics: Area Under Curve; Bronchopneumonia; Ciprofloxacin; Community-Acquired Infections; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Moxifloxacin; Pneumococcal Infections; Respiratory Tract Infections; Streptococcus pneumoniae	2014
Impact of poor compliance with levofloxacin and moxifloxacin on respiratory tract infection antimicrobial efficacy: a pharmacokinetic/pharmacodynamic simulation study. International journal of antimicrobial agents, 2015, Volume: 45, Issue:1 Topics: Adult; Anti-Bacterial Agents; Fluoroquinolones; Haemophilus influenzae; Humans; Levofloxacin; Male; Medication Adherence; Middle Aged; Models, Statistical; Moraxella catarrhalis; Moxifloxacin; Respiratory Tract Infections; Streptococcus pneumoniae; Treatment Failure; Young Adult	2015
Factors associated with antibiotic misuse in outpatient treatment for upper respiratory tract infections. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:7 Topics: Ambulatory Care; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Azithromycin; Centers for Disease Control and Prevention, U.S.; Drug Utilization; Female; Fluoroquinolones; Humans; Inappropriate Prescribing; Male; Middle Aged; Moxifloxacin; Multivariate Analysis; Outpatients; Practice Patterns, Physicians'; Respiratory Tract Infections; Retrospective Studies; United States	2015
Pharmacokinetics of consecutive oral moxifloxacin (400 mg/day) in patients with respiratory tract infection. Therapeutic advances in respiratory disease, 2016, Volume: 10, Issue:1 Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Bacterial Agents; Area Under Curve; Female; Fluoroquinolones; Humans; Japan; Male; Middle Aged; Moxifloxacin; Respiratory Tract Infections	2016
[Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from class B hospitals in China during 2013 and 2014]. Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2016, Volume: 39, Issue:1 Topics: Anti-Bacterial Agents; Aza Compounds; Cefepime; Cephalosporins; China; Clarithromycin; Community-Acquired Infections; Drug Resistance, Bacterial; Fluoroquinolones; Haemophilus influenzae; Humans; Klebsiella pneumoniae; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Penicillins; Respiratory Tract Infections; Staphylococcus aureus; Streptococcus pneumoniae	2016
Zabofloxacin for chronic bronchitis. Drugs of today (Barcelona, Spain : 1998), 2016, Volume: 52, Issue:9 Topics: Anti-Infective Agents; Bronchitis, Chronic; Clinical Studies as Topic; Drug Administration Routes; Drug Evaluation, Preclinical; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Moxifloxacin; Respiratory Tract Infections; Treatment Outcome	2016
Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study). International journal of antimicrobial agents, 2009, Volume: 33, Issue:1 Topics: Adolescent; Adult; Anti-Bacterial Agents; Aza Compounds; Bacteria; Drug Resistance, Bacterial; Female; Fluoroquinolones; Germany; Haemophilus influenzae; Hospitalization; Humans; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Moraxella catarrhalis; Moxifloxacin; Prevalence; Quinolines; Respiratory Tract Infections; Staphylococcus aureus; Streptococcus pneumoniae; Young Adult	2009
Moxifloxacin: new indication. Inadequate restriction of indications in ENT and respiratory infections. Prescrire international, 2009, Volume: 18, Issue:103 Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Bronchitis; Chemical and Drug Induced Liver Injury; Europe; Fluoroquinolones; Humans; Long QT Syndrome; Moxifloxacin; Pneumococcal Infections; Quinolines; Respiratory Tract Infections; Safety-Based Drug Withdrawals; Sinusitis; Stevens-Johnson Syndrome	2009
Comparative in vitro activity of sitafloxacin against bacteria isolated from Thai patients with urinary tract infections and lower respiratory tract infections. Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2012, Volume: 95 Suppl 2 Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Respiratory Tract Infections; Thailand; Urinary Tract Infections	2012
[Severe pseudouveitis associated with moxifloxacin therapy]. Journal francais d'ophtalmologie, 2013, Volume: 36, Issue:2 Topics: Anti-Bacterial Agents; Aza Compounds; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Quinolines; Respiratory Tract Infections; Severity of Illness Index; Sinusitis; Uveitis	2013
Drug-induced immune thrombocytopenia due to moxifloxacin. BMJ case reports, 2013, Jan-17, Volume: 2013 Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Diagnosis, Differential; Female; Fluoroquinolones; Humans; Immunity, Cellular; Moxifloxacin; Platelet Count; Quinolines; Respiratory Tract Infections; Thrombocytopenia	2013
In vitro activity of moxifloxacin against recent community-acquired respiratory tract pathogens isolated in France: a national survey. International journal of antimicrobial agents, 2002, Volume: 20, Issue:3 Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Data Collection; Drug Resistance, Bacterial; Female; Fluoroquinolones; France; Genes, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Polymerase Chain Reaction; Quinolines; Respiratory Tract Infections	2002
[Respiratory tract infections. Increasingly more established antibiotics fail]. MMW Fortschritte der Medizin, 2002, Oct-17, Volume: 144, Issue:42 Topics: Anti-Infective Agents; Aza Compounds; Bacterial Infections; Drug Resistance, Multiple; Fluoroquinolones; Humans; Moxifloxacin; Quinolines; Respiratory Tract Infections; Treatment Outcome	2002
[In vitro activity of moxifloxacin against respiratory pathogens in Latin America]. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2002, Volume: 15, Issue:4 Topics: Anti-Infective Agents; Aza Compounds; Fluoroquinolones; Haemophilus influenzae; Humans; Latin America; Moraxella catarrhalis; Moxifloxacin; Quinolines; Respiratory Tract Infections; Staphylococcus aureus; Streptococcus pneumoniae; Streptococcus pyogenes	2002
Bactericidal activities of methoxyfluoroquinolones gatifloxacin and moxifloxacin against aerobic and anaerobic respiratory pathogens in serum. Antimicrobial agents and chemotherapy, 2003, Volume: 47, Issue:4 Topics: Adult; Anti-Infective Agents; Area Under Curve; Aza Compounds; Bacteria, Aerobic; Bacteria, Anaerobic; Community-Acquired Infections; Fluoroquinolones; Gatifloxacin; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Quinolines; Respiratory Tract Infections	2003
National surveillance programme on susceptibility patterns of respiratory pathogens in South Africa: moxifloxacin compared with eight other antimicrobial agents. Journal of clinical pathology, 2003, Volume: 56, Issue:5 Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Haemophilus influenzae; Humans; Microbial Sensitivity Tests; Moxifloxacin; Population Surveillance; Quinolines; Respiratory Tract Infections; South Africa; Streptococcus pneumoniae; Streptococcus pyogenes	2003
Comparative in vitro activities of three new quinolones and azithromycin against aerobic pathogens causing respiratory tract and abdominal wound infections. Chemotherapy, 2004, Volume: 50, Issue:1 Topics: Abdominal Injuries; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Bacteria, Aerobic; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Respiratory Tract Infections; Wound Infection	2004
In vitro activity of moxifloxacin against community respiratory pathogens in Qatar. International journal of antimicrobial agents, 2004, Volume: 24, Issue:3 Topics: Anti-Bacterial Agents; Aza Compounds; beta-Lactamases; Fluoroquinolones; Haemophilus influenzae; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Penicillin Resistance; Qatar; Quinolines; Respiratory Tract Infections; Streptococcus pneumoniae	2004
[Moxifloxacin in general practice. Economical concept]. MMW Fortschritte der Medizin, 2004, Nov-11, Volume: 146, Issue:46 Topics: Aza Compounds; Bacterial Infections; Clinical Trials as Topic; Cost Savings; Fluoroquinolones; Humans; Moxifloxacin; Quinolines; Respiratory Tract Infections; Treatment Outcome	2004
Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens. Antimicrobial agents and chemotherapy, 2005, Volume: 49, Issue:4 Topics: Anti-Infective Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Quinolones; Respiratory Tract Infections; Streptococcus pneumoniae	2005
Efficacy and tolerability of moxifloxacin in patients with respiratory tract infections treated in general practice: Results of a post-marketing surveillance study. Clinical drug investigation, 2006, Volume: 26, Issue:9 Topics: Adult; Aged; Anti-Infective Agents; Aza Compounds; Family Practice; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Product Surveillance, Postmarketing; Prospective Studies; Quinolines; Respiratory Tract Infections	2006
parE mutations in Streptococcus pneumoniae may reduce bactericidal activity of respiratory fluoroquinolones. International journal of antimicrobial agents, 2007, Volume: 29, Issue:2 Topics: Anti-Bacterial Agents; Aza Compounds; DNA Topoisomerase IV; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Respiratory Tract Infections; Streptococcus pneumoniae	2007
Treatment of respiratory tract infections with moxifloxacin: results of postmarketing surveillance in China. International journal of clinical practice, 2007, Volume: 61, Issue:9 Topics: Adult; Aged; Anti-Infective Agents; Aza Compounds; China; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Product Surveillance, Postmarketing; Prospective Studies; Quinolines; Respiratory Tract Infections	2007
Electroconvulsive therapy and antibiotics: a case report. The journal of ECT, 2007, Volume: 23, Issue:4 Topics: Aged, 80 and over; Anti-Infective Agents; Aza Compounds; Cross Infection; Depressive Disorder, Major; Electroconvulsive Therapy; Electroencephalography; Female; Fluoroquinolones; Humans; Moxifloxacin; Quinolines; Recurrence; Respiratory Tract Infections; Retreatment	2007
BAY 12-8039, a novel fluoroquinolone. Activity against important respiratory tract pathogens. Diagnostic microbiology and infectious disease, 1998, Volume: 32, Issue:1 Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; beta-Lactamases; Fluoroquinolones; Haemophilus influenzae; Humans; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Quinolines; Respiratory Tract Infections; Sensitivity and Specificity; Species Specificity	1998
[National multicenter study of the in vitro activity of moxifloxacin against respiratory tract pathogens. Spanish Study Group on Moxifloxacin]. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2000, Volume: 13, Issue:1 Topics: Anti-Infective Agents; Aza Compounds; Fluoroquinolones; Haemophilus influenzae; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Quinolines; Respiratory Tract Infections; Staphylococcus aureus; Streptococcus	2000
Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States. Antimicrobial agents and chemotherapy, 2000, Volume: 44, Issue:10 Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Cloning, Molecular; DNA Gyrase; DNA Topoisomerase IV; DNA Topoisomerases, Type II; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Genotype; Haemophilus influenzae; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Phenotype; Quinolines; Respiratory Tract Infections; Reverse Transcriptase Polymerase Chain Reaction; Streptococcus pneumoniae; United States	2000
Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens. International journal of antimicrobial agents, 2001, Volume: 18, Issue:4 Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Community-Acquired Infections; Fluoroquinolones; Haemophilus influenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Respiratory Tract Infections; Streptococcus pneumoniae; Streptococcus pyogenes	2001
Susceptibility to moxifloxacin and other antimicrobial agents of major pathogens responsible for community acquired respiratory tract infection in Poland. International journal of antimicrobial agents, 2002, Volume: 19, Issue:1 Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; Community-Acquired Infections; Fluoroquinolones; Haemophilus influenzae; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Penicillin Resistance; Poland; Quinolines; Respiratory Tract Infections; Streptococcus pneumoniae; Streptococcus pyogenes	2002
In vitro activity of moxifloxacin against local bacterial isolates. Annals of the Academy of Medicine, Singapore, 2001, Volume: 30, Issue:6 Topics: Anti-Infective Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Moxifloxacin; Quinolines; Respiratory Tract Infections	2001
Moxifloxacin sensitivity of respiratory pathogens in the United Kingdom. Journal of chemotherapy (Florence, Italy), 2002, Volume: 14, Issue:1 Topics: Anti-Infective Agents; Aza Compounds; Fluoroquinolones; Haemophilus influenzae; Humans; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Quinolines; Respiratory Tract Infections; Streptococcus pneumoniae; United Kingdom	2002